Policy Pulse — Global Spillover — 03 Jul 2026
🌍 USTR Section 301 Forced Labor Tariffs: 12.5% Proposed on India — Negative for Pharma, Textiles, IT
Date: 03 Jul 2026
Category: Trade War — USTR Section 301
Tickers impacted: SUNPHARMA, DRREDDY, CIPLA, AUROPHARMA, DIVISLAB, WELSPUN, TRIDENT, VARDHMAN, TCS, INFY, WIPRO, HCLTECH
Executive Summary
The Office of the United States Trade Representative (USTR) has proposed 12.5% additional tariffs on imports from 54 economies — including India, China, Vietnam, Japan, South Korea, Brazil, Switzerland, and the UK — under Section 301 investigations into forced labor import enforcement. The comment deadline is July 6, 2026, with hearings on July 7, 2026. A final decision is expected in late July, potentially before the Section 122 tariffs expire on July 24.
This is a direct negative for Indian exports to the US market. Export-oriented Indian sectors — pharma, textiles, and IT services — face margin compression and competitive disadvantage vs. countries with lower proposed rates or exemptions.
Key Facts
| Detail | Value |
|---|---|
| Proposed tariff | 12.5% additional on Indian imports |
| Countries affected | 54 economies (incl. India, China, Japan, Vietnam) |
| Lower rate (10%) | Canada, EU, Indonesia, Mexico, Pakistan — those with partial forced labor bans |
| Current Section 122 tariff | 10% across-the-board (expires Jul 24, 2026 unless extended) |
| If Section 122 expires + Section 301 imposed | Net tariff on Indian goods = ~12.5% (from current ~10%) |
| If Section 122 extended + Section 301 imposed | Net tariff = ~22.5% (worst case) |
| Legal basis | Section 301 vs. IEEPA. 301 has stronger legal footing after CIT ruled against Section 122 |
| Comments deadline | July 6, 2026 |
| Hearings | July 7, 2026 |
| Final decision | Late July 2026 |
| India's response | Engaged diplomatically, seeking termination within BTA framework |
🇮🇳 Impact on Indian Sectors
1. Pharma — Most Exposed
Indian pharma exports to the US were $8.6B in 2024 (largest export category). A 12.5% tariff would directly compress generic drug margins (already thin at 15-20% EBITDA).
| Stock | Ticker | Impact | Reason |
|---|---|---|---|
| Sun Pharma | SUNPHARMA | 🔴 Sell | ~30% of revenue from US generics. 12.5% tariff = ~100-150 bps margin hit |
| Dr Reddy's | DRREDDY | 🔴 Sell | ~45% of revenue from US. Most exposed among Indian pharma. Tariff could compress US margins from ~25% to ~20% |
| Cipla | CIPLA | 🔴 Sell | ~30% US revenue exposure. Inhaler and generic portfolio face tariff |
| Aurobindo Pharma | AUROPHARMA | 🔴 Sell | ~50% of revenue from US. Highest US exposure among peers |
| Divi's Labs | DIVISLAB | 🟡 Hold | Less direct US finished dosage exposure. More API/CRM business. Lower tariff risk |
| Lupin | LUPIN | 🔴 Sell | ~35% US revenue. Generic portfolio at risk |
Confidence: 4/5 — Direct tariff mechanism. Pharma is the largest export category. Margin math is clear.
Mitigation: India can negotiate exemptions under Bilateral Trade Agreement (BTA) framework. Negotiations ongoing.
2. Textiles — Second Most Exposed
Indian textile exports to the US were significant (~$8-9B in 2024). The USTR notice mentions a textile mechanism allowing reduced rates for certain apparel volumes, but the details are not finalized.
| Stock | Ticker | Impact | Reason |
|---|---|---|---|
| Welspun India | WELSPUN | 🔴 Sell | ~40% of revenue from US (home textiles). 12.5% tariff = competitive disadvantage vs China/Pakistan |
| Trident | TRIDENT | 🔴 Sell | ~30% US exposure (towels, sheets). Margin sensitive to tariff pass-through |
| Vardhman Textiles | VARDHMAN | 🔴 Sell | ~25% US exposure. Yarn/fabric exports at risk |
| Page Industries | PAGE | 🟡 Hold | Domestic-focused (Jockey brand in India). Minimal US export exposure |
| KPR Mill | KPRMILL | 🔴 Sell | ~30% US export exposure. Vertically integrated but still tariff-vulnerable |
Confidence: 3/5 — Textile mechanism could provide partial relief. Final rates unclear.
3. IT Services — Indirect Risk
Indian IT firms derive 50-65% of revenue from US clients. The tariff is not on services (Section 301 covers goods), but the indirect risks are real:
- US clients may cut IT spending if tariffs raise costs
- H-1B visa policy could tighten alongside trade friction
- The forced labor framing could extend to H-1B wage investigations
| Stock | Ticker | Impact | Reason |
|---|---|---|---|
| TCS | TCS | 🟡 Hold | ~50% US revenue. Indirect risk via client spending. Strong delivery cushion |
| Infosys | INFY | 🟡 Hold | ~60% US revenue. Most exposed among Top 3. H-1B scrutiny risk |
| Wipro | WIPRO | 🟡 Hold | ~55% US revenue. Consulting + BPO vulnerable |
| HCL Tech | HCLTECH | 🟡 Hold | ~55% US revenue. Product/platform revenue less vulnerable than services |
Confidence: 2/5 — Indirect, not direct. IT services are not goods and not subject to Section 301 tariffs directly.
4. Gems & Jewellery — At Risk
India exported $5.3B of gems & jewellery to US in 2024. Cut/polished diamonds and studded jewellery face the 12.5% tariff.
| Stock | Ticker | Impact | Reason |
|---|---|---|---|
| Titan | TITAN | 🟡 Hold | Domestic-focused (Jewelry revenue 90% India). Minimal direct export exposure |
| Kalyan Jewellers | KALYANKJIL | 🟡 Hold | Domestic + Middle East focused. Low US direct exposure |
| PC Jeweller | PCJEWELLER | 🟡 Hold | Domestic play. Limited US export risk |
Confidence: 2/5 — Most jewelry stocks are domestic-focused.
🇮🇳 India vs. Peers: Tariff Comparison
| Country | Proposed Sec 301 Rate | Current Sec 122 Rate | Worst Case Combined |
|---|---|---|---|
| India | 12.5% | 10% | 22.5% |
| China | 12.5% | 125% (existing) | ~137.5% |
| Pakistan | 10% | 10% | 20% |
| Indonesia | 10% | 10% | 20% |
| EU | 10% | 10% | 20% |
| Vietnam | 12.5% | 10% | 22.5% |
| Japan | 12.5% | 15% (bilateral deal) | 27.5% |
Key insight: Pakistan and Indonesia (India's competitors in textiles) get a lower 10% rate, giving them a 2.5% pricing advantage over India in the US market.
🛡️ Bilateral Trade Agreement (BTA) — The Escape Valve
India is currently negotiating a Bilateral Trade Agreement with the US, with US Deputy USTR Brendan Lynch in New Delhi for talks (ending June 4). The agreement framework (announced Feb 6, 2026) already reduced US tariffs on Indian goods from 50% to 18%.
India's ask:
- Terminate Section 301 investigations through the BTA framework
- Secure tariff rates lower than competitors
- Extend duty-free access for pharma generics
Likelihood of relief: Medium-high. India has leverage through:
- Defence cooperation pivot (India stopped buying Russian oil per Feb 2026 deal)
- Geopolitical alignment against China
- $500B purchasing intent commitment
- Strong bilateral relationship with Trump
📊 Sector Impact Summary
| Sector | Direction | Key Stocks | Confidence |
|---|---|---|---|
| Pharma | 🔴 Bearish | SUNPHARMA, DRREDDY, CIPLA, AUROPHARMA | 4/5 |
| Textiles | 🔴 Bearish | WELSPUN, TRIDENT, VARDHMAN | 3/5 |
| IT Services | 🟡 Neutral-Negative | TCS, INFY, WIPRO, HCLTECH | 2/5 |
| Gems & Jewellery | 🟡 Neutral | TITAN, KALYANKJIL | 2/5 |
⏰ Key Dates
| Date | Event | Impact |
|---|---|---|
| Jul 6 | Written comments deadline for USTR Section 301 | Final chance for industry input |
| Jul 7 | USTR Section 301 public hearings | Market-moving if India's rate is adjusted |
| Late Jul | Final determination expected | 12.5% could be finalized or adjusted |
| Jul 24 | Section 122 tariffs expire (unless extended) | Combined tariff impact depends on this |
📌 Bottom Line
The 12.5% USTR tariff is a real negative for Indian pharma (Dr Reddy's, Aurobindo most exposed) and textiles (Welspun, Trident). However, the BTA negotiations provide a credible escape route. Expect India to push for termination of Section 301 investigations within the BTA framework.
Actionable trades:
- 🔴 Sell Dr Reddy's, Aurobindo, Welspun — highest US tariff exposure
- 🟡 Hold Sun Pharma, Cipla, Trident — exposure but with BTA mitigation potential
- 🟡 Hold TCS, Infosys — indirect risk only, services not tariffed
- 🟢 Watch — If BTA excludes pharma from tariffs, DRREDDY, CIPLA become buys
This is a global spillover analysis combining US policy with impact on Indian stocks.
Disclaimer: For informational purposes only. Not investment advice. All impacts are directional assessments based on policy news flow as of 03 Jul 2026.